Objective: The positive effect of antidiabetic medication on cognitive decline has been given some support by, among others, Secnik et al (2021) and Secnik et al (2022). However, as they are observational studies, it is not clear whether the effect is causal.
Research design and methods: Using the Swedish Dementia Registry and supplementary Swedish registers/databases, we identified 1,873 patients (4,732 observations) with diagnosis of diabetes and Alzheimer’s disease or mixed-pathology dementia who were followed-up at least once after dementia diagnosis. The association of use of metformin with Mini-Mental State Examination scores in patients with diabetes and dementia was studied in two ways. 1) The difference between the last and the first score for each patient was compared with treatment (use of metformin) and subjected to a new sensitivity analysis. 2) The difference between scores for each patient at the points in time when there was a change in use of metformin (either start of use, or discontinuation of use) was studied.
Results: There is an association between cognitive decline and use of metformin. However, any conclusion of a causal relationship is tenuous.
Conclusion: The present study offers no basis for causal conclusions, but given the association, further examination of cognitive effects of metformin is warranted.